The use of tacrolimus in pediatric liver transplantation

Journal of Pediatric Gastroenterology and Nutrition

Volumn 26, Issue 1, 1998, Pages 90-102

  McDiarmid, S V ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CARBAMAZEPINE; CLARITHROMYCIN; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; TACROLIMUS; VERAPAMIL;

DRUG HALF LIFE; DRUG POTENCY; GRAFT REJECTION; GRAFT SURVIVAL; HELPER CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; TACROLIMUS;

EID: 0031973628     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199801000-00016     Document Type: Review

References (97)

1. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from a Streptomyces II. Immunosuppressive effect of FK506 in vitro. J Antibiot 1987;40:1256-65.
2. Johansson A, Moller E. Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. Transplantation 1990;50:1001-7.
3. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989;143:718-26.
4. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987;139:1797-803.
5. Yoshimura N, Matsui S, Hamashima T, Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 1989;47:351-6.
6. Morris RE, Wu J, Shorthouse R. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. Transplant Proc 1990;22:110-2.
7. Suthanthiran M, Morris RE, Strom TB. Immunosuppressants: Cellular and molecular mechanisms of action. Am J Kidney Dis 1996;28:159-72.
8. Schreiber SL, Liu J, Albers MW, et al. Immunophilin-ligand complexes as probes of intracellular signaling pathways. Transplant Proc 1991;23:2839-44.
9. Liu J, Farmer JDJ, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-15.
10. Flanagan M, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991;352:803-7.
11. Sigal NH, Dumont FJ, Siekierka JJ, Wiederrecht G, Parent SA, Brizuela L. Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? Transplant Proc 1991;23:2846-9.
12. Starzl TE, Todo S, Fung JJ, Demetris AJ, Venkataramanan R, Jain A. FK506 for human liver, kidney, and pancreas transplantation. Lancet 1989;2:1000-4.
13. Jain A, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK506 pharmacokinetics and trough concentrations. Transplant Proc 1990;22:57-9.
14. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991;23:2736-40.
15. Venkataramanan R, Jain A, Cadoff E, et al. Pharmacokinetics of FK506: Preclinical and clinical studies. Transplant Proc 1991;22:52-6.
16. Pichard L, Fabre J, Domergue J, Joyeux H, Maurel P. Effect of FK 506 on human hepatic cytochromes P-450: Interaction with Cya. Transplant Proc 1991;23:2791-3.
17. Jain A, Fung JJ, Venkataramanan R, et al. Comparative study of cyclosporine and FK506 dosage requirement in adult and pediatric orthotopic liver transplantation. Transplant Proc 1991;23:2763-6.
18. McDiarmid SV, Colonna JO, Shaked A, Vargas J, Ament ME, Busuttil RW. Differences in oral FK506 dose requirements between adult and pediatric. Transplantation 1993;55:1328-32.
19. Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 1995;27:1108-10.
20. Cadoff EM, Venkataramanan R, Krajack A, et al. Assay of FK 506 in plasma. Transplant Proc 1990;22:50-1.
21. Beysens AJ, Wijnen RM, Beuman GH, van der Heyden J, Kootstra G, van As H. FK 506: Monitoring in plasma or in whole blood? Transplant Proc 1991;23:2745-7.
22. Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 1991;23:2748-9.
23. Winkler M, Ringe B, Baumann J, Loss M, Wonigeit K, Pichlmayr R. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression [see comments]. Clin Chem 1994;40:2247-53.
24. Abu-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function with particular reference to the liver. Transplantation 1991;52:71-7.
25. Esquivel CO, So SK, McDiarmid SV, Andrews WS, Colombani PM. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients [letter]. Transplantation 1996;61:847-8.
26. McMichael J, Irish W, McCauley J, et al. Evaluation of a novel 'intelligent' dosing system for optimizing FK506 therapy.. Transplant Proc 1991;23:2780-2.
27. Todo S, Fung JJ, Demetris AJ, Jain A, Venkataramanan R, Starzl TE. Early trials with FK506 as primary treatment in liver transplantation. Transplant Proc 1990;22:13-6.
28. McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. Transplantation 1995;59:530-6.
29. Tzakis AG, Reyes J, Todo S, et al. Two-year experience with FK 506 in pediatric patients. Transplant Proc 1993;25:619-21.
30. Uemoto S, Tanaka K, Honda K, et al. Experience with FK506 in living-related liver transplantation. Transplantation 1993;55:288-92.
31. Ueda M, Uemoto S, Inomata Y, et al. A proposal of FK506 optimal dosing in living related liver transplantations. Transplantation 1995;60:258-64.
32. Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996;61:247-52.
33. Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996;61:1188-92.
34. McDiarmid SV, Gornbein JA, Fortunat M, et al. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation 1992;53:109-15.
35. Fung JJ, Todo S, Jain A, et al. Conversion from cyclosporine to FK506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc 1990;22:6-12.
36. McDiarmid SV, Klintmalm GBG, Busuttil RW. FK506 rescue therapy in liver transplantation: Outcome and complications. Transplant Proc 1991;23:2996-9.
37. D'Allesandro AM, Kalayoglu M, Pirsch JD, et al. FK506 rescue therapy for resistant rejection episodes in liver transplant recipients. Transplant Proc 1991;23:2987-8.
38. Lewis WD, Jenkins RL, Burke PA, et al. FK506 rescue therapy in liver transplant recipients with drug-resistant rejection. Transplant Proc 1991;23:2989-91.
39. Winkler M, Ringe B, Gerstenkorn C, et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. Transplant Proc 1991;23:2984-6.
40. Shaw BW, Markin R, Stratta R, Langnas A, Donovan J, Sorrell M. FK506 for rescue treatment of acute and chronic rejection in liver allograft recipients. Transplant Proc 1991;23:2994-5.
41. McDiarmid SV, Klintmalm GBG, Busuttil RW. FK506 conversion for intractable rejection of the liver allograft. Transplant Intl 1993;6:305-12.
42. Reding R, Wallemacq PE, Lamy ME, et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Transplantation 1994;57:93-100.
43. Egawa H, Esquivel CO, So SK, Cox K, Concepcion W, Lawrence L. FK506 conversion treatment in pediatric liver transplantation. Transplantation 1994;57:1169-73.
44. McDiarmid SV, Wallace P, Vargas J, Ament ME, Busuttil RW. The treatment of intractable rejection with FK506 in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 1995;20:291-9.
45. Shapiro R, Fung JJ, Jain A, Parks P, Todo S, Starzl TE. The side effects of FK506 in humans. Transplant Proc 1990;22:35-6.
46. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991;23:3105-8.
47. McCauley J, Fung JJ, Jam A, Todo S, Starzl TE. The effects of FK506 on renal function after liver transplantation. Transplant Proc 1990;22:17-20.
48. Fung JJ, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine. Transplant Proc 1991;23:2977-83.
49. Todo S, Fung JJ, Tzakis A, et al. One hundred ten consecutive primary orthotopic liver transplants under FK506 in adults. Transplant Proc 1991;23:1397-402.
50. McDiarmid SV, Colonna JO, Shaked A, Ament ME, Busuttil RW. A comparison of renal function in cyclosporine and FK506 treated patients after primary orthotopic liver transplantation. Transplantation 1993;56:847-53.
51. McCauley J, Takaya S, Fung JJ, et al. The question of FK506 nephrotoxicity after liver transplantation. Transplant Proc 1991;23:1444-7.
52. Moutabarrik A, Ishibashi M, Kameoka H, et al. In vitro FK 506 kidney tubular cell toxicity. Transplant Proc 1991;23:3137-40.
53. McCauley J, Fung JJ, Todo S, Jain A, Deballi P, Starzl TE. Changes in renal function after liver transplantation under FK506. Transplant Proc 1991;23:3143-5.
54. McCauley J, Studer R, Craven P, Murray S. The effects of cyclosporine A, cyclosporine G, and FK 506 upon prostaglandin production in renal mesangial cells in culture. Transplant Proc 1991;23:3141-2.
55. Moutabarrik A, Ishibashi M, Fukunaga M, et al. FK506 mechanism of nephrotoxicity: Stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. Transplant Proc 1991;23:3133-6.
56. Morris SM, Kepka-Lenhart D, Curthoys NP, McGill RL, Marcus RJ, Adler S. Disruption of renal function and gene expression by FK506 and cyclosporine. Transplant Proc 1991;23:3116-8.
57. Eidelman BH, Abu-Elmagd K, Wilson JM, et al. Neurologic complications of FK506. Transplant Proc 1991;23:3175-8.
58. Mueller AR, Platz KP, Bechstein WO, et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994;58:155-70.
59. Lopez OL, Martinez AJ, Torre-Cisneros J. Neuropathologic findings in liver transplantation: A comparative study. Transplant Proc 1991;23:3181-2.
60. Van Thiel DH, Iqbal M, Jain A, Fung J, Todo S, Starzl TE. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK506 in liver transplantation. Transplant Proc 1990;22:37-40.
61. Steinmuller TM, Graf KJ, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial. Transplantation 1994;58:669-74.
62. Jindal RM, Popescu I, Emre S, et al. Serum lipid changes in liver transplant recipients in a prospective. Transplantation 1994;57:1395-8.
63. Krentz AJ, Dmitrewski J, Mayer D, et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. Transplantation 1994;57:1666-9.
64. Mieles L, Gordon RD, Mintz D, Toussaint RM, Imventarza O, Starzl TE. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Transplant Proc 1991;23:949-53.
65. Tamura K, Fujimura T, Tsutsumi T, et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. Transplant Proc 1995;27:357-61.
66. Atkison P, Joubert G., Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894-6.
67. Dollinger MM, Plevris JN, Chauhan A, MacGilchrist AJ, Finlayson ND, Hayes PC. Tacrolimus and cardiotoxicity in adult liver transplant recipients [letter]. Lancet 1995;346:507
68. Park SC, Beerman LB, Gartner JC, et al. Echocardiographic findings before and after liver transplantation. Am J Cardiol 1985;55:1373-8.
69. Singh N, Gayowski T, Wagener M, Yu VL. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. Transplantation 1994;58:774-8.
70. Alessiani M, Kusne S, Martin M, et al. Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc 1991;23:1501-3.
71. Malatack JJ, Gartner JC, Urbach AH, Zitelli BJ. Othotopic liver transplantation. Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: A growing concern. J Pediatr 1991;118:667-75.
72. Sokol EM, Caragiozoglou T, Lamy M, Reding R, OTTE J. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993;56:1394-8.
73. Penn I. Cancers complicating organ transplantation [editorial; comment]. N Engl J Med 1990;323:1767-9.
74. Mathur A, Kamat DM, Filipovich AH, Steinbuch M, Shapiro RS. Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders. Transplantation 1994;57:1042-5.
75. Burman K, Crawford DH. Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells [letter]. Lancet 1991;337:297-8.
76. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988;45:719-27.
77. Lamy M, Favart AM, Cornu C, et al. Epstein-Barr virus infection in 59 orthotopic liver transplant patients. Med Microbiol Immunol 1990;179:137-44.
78. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995;59:524-9.
79. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of posttransplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
80. Rustgi VK. Epstein-Barr viral infection and posttransplantation lymphoproliferative disorders. Liver Transplantation Surgery 1995;1:100-8.
81. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996;62:370-5.
82. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors. N Engl J Med 1995;332:19-25.
83. Markin RS. Manifestations of Epstein-Barr virus-associated disorders in liver. Liver 1994;14:1-13.
84. Cao S, Cox K, Esquivel CO, et al. PTLD and gastrointestinal manifestations of EBV infection in children following liver transplantation. Abstract presented at American Society Transplant Physicians Dallas, May 1996.
85. Nalesnik MA, Lacker J, Jaffe R, et al. Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplantation 1992;6:249-52.
86. Renard TH, Andrews W, Foster ME. Relationship between OKT3 administration. EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipient. Transplant Proc 1991;23:1473-6.
87. Alfrey EJ, Friedman AL, Grossman RA, et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation 1992;54:250-3.
88. Benkerrou M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 1993;7:467-75.
89. Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin [letter]. N Engl J Med 1988;318:1334.
90. Taguchi Y, Purtilo DT, Okano M. The effect of intravenous immunoglobulin and interferon-alpha on Epstein-Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 1994;57:1813-5.
91. Green M, Reyes J, Jabbour N, et al. Use of quantitative PCR to predict onset of Epstein-Barr viral infection and posttransplant lymphoproliferative disease after intestinal transplantation in children. Transplant Proc 1996;28:2759-60.
92. Martinez OM, Villanueva JC, Lawrence-Miyasaki LS, Quinn MB, Cox K, Krams SM. Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation 1995;59:519-24.
93. Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-I gene) in liver specimens from transplant recipients with posttransplantation lymphoproliferative disease. N Engl J Med 1992;327:1710-4.
94. Kato H, Inamoto T, Nakamura H, et al. Soluble CD23 as a sensitive marker for Epstein-Barr virus-related disorders after liver transplantation. Transplantation 1993;56:1109-13.
95. Badley AD, Portela DF, Patel R, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transplant Surf; 1996;2:375-82.
96. Lake JR, Gorman KJ, Esquivel CO, et al. The impact of immuno-suppressive regimens on the cost of liver transplantation - results from the U.S. FK506 multicenter trial. Transplantation 1995;60:1089-95.
97. Groth CG, Ohlman S, Gannedahl G, Ericzon BG. New immuno-suppressive drugs in transplantation. Transplant Proc 1993;25:2681-3.